Elanco Animal Health Incorporated's Revenue in the fiscal year 2025 $ 4,715.00 millions
Elanco Animal Health Incorporated's Revenue in the fiscal year 2024 $ 4,439.00 millions
Elanco Animal Health Incorporated's Revenue in the fiscal year 2023 $ 4,417.00 millions
Elanco Animal Health Incorporated's Revenue in the fiscal year 2022 $ 4,411.00 millions
Elanco Animal Health Incorporated's Revenue in the fiscal year 2021 $ 4,765.00 millions
ELAN Revenue second quarter 2026 Y/Y Growth Comment
Elanco Animal Health Incorporated achieved in the second quarter 2026, above Company average Revenue increase of 10.23% year on year, to $ 1,368.00 millions.
Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 119 other companies have achieved higher Revenue growth. While Elanco Animal Health Incorporated' s Revenue growth of 10.23% ranks overall at the positon no. 2502 in the second quarter 2026.
ELAN Revenue ( Y/Y Growth %)
2026
2025
2024
2023
4th Quarter
December
-
12.16 %
-1.45 %
5.5 %
3rd Quarter
September
-
10.39 %
-3.56 %
3.89 %
2nd Quarter
June
10.23 %
4.81 %
12.02 %
-10.2 %
1st Quarter
March
14.92 %
-1 %
-4.14 %
2.61 %
FY
-
6.22 %
0.5 %
-
Financial Statements
Elanco Animal Health Incorporated's second quarter 2026 Revenue
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Elanco Animal Health Incorporated's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
51.73 %
2.61 %
-16.43 %
(Sep 30 2020)
ELAN's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2026 Elanco Animal Health Incorporated disclosed decrease in Revenue from the first quarter by -0.22% to $ 1,368.00 millions, from $ 1,371.00 millions achived in the previous reporting period.
Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.
Within Major Pharmaceutical Preparations industry 84 other companies have achieved higher Revenue quarter on quarter growth. While Elanco Animal Health Incorporated's Revenue growth quarter on quarter, overall rank is 1826.
In the II. Quarter 2026 Elanco Animal Health Incorporated disclosed decrease in Revenue from the first quarter by -0.22% to $ 1,368.00 millions, from $ 1,371.00 millions achived in the previous reporting period.
Although periodic circumstance commonly energize II. Quarter 2026 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.
Within Major Pharmaceutical Preparations industry 84 other companies have achieved higher Revenue quarter on quarter growth. While Elanco Animal Health Incorporated's Revenue growth quarter on quarter, overall rank is 1826.
Elanco Animal Health Incorporated's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 30 2026)
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending
$ 5,020.00
$ 4,893.00
$ 4,715.00
$ 4,591.00
$ 4,484.00
Y / Y Revenue Growth (TTM)
11.95 %
10.53 %
6.22 %
3.08 %
-0.18 %
Year on Year Revenue Growth Overall
Ranking
# 2643
# 2181
# 1831
# 1896
# 1189
Seqeuential Revenue Change (TTM)
2.6 %
3.78 %
2.7 %
2.39 %
1.29 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2502
# 2334
# 1464
# 2168
# 1269
Cumulative Revenue growth Comment
Elanco Animal Health Incorporated saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 11.95% year on year, to $ 5,020 millions if the fiscal year would have ended in Jun 30 2026. Elanco Animal Health Incorporated's trailing twelve months Revenue growth was higher than company's average 7.78% and higher than 10.53% growth in Mar 31 2026. But from twelve months ended Mar 31 2026 rise was beneth at 2.6 % from $4893 millions achieved in the period from Mar 31 2026 to Jun 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at7.78%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 2.6 % increase from $4893 millions in the period from Mar 31 2026 to Jun 30 2025.
In the Healthcare sector 378 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2181 to 2643.
Elanco Animal Health Incorporated saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 11.95% year on year, to $ 5,020 millions if the fiscal year would have ended in Jun 30 2026. Elanco Animal Health Incorporated's trailing twelve months Revenue growth was higher than company's average 7.78% and higher than 10.53% growth in Mar 31 2026. But from twelve months ended Mar 31 2026 rise was beneth at 2.6 % from $4893 millions achieved in the period from Mar 31 2026 to Jun 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at7.78%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 2.6 % increase from $4893 millions in the period from Mar 31 2026 to Jun 30 2025.
In the Healthcare sector 378 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2181 to 2643.
About Elanco Animal Health Incorporated Revenue Growth Rates (ELAN), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
17.83%